PE-backed StageBio merges with Alizée Pathology

StageBio has merged with Alizée Pathology to form a provider of specialized histology, pathology, biomarker development and archiving services for the biopharmaceutical, medical device and contract research industries. No financial terms were disclosed. StageBio is a portfolio company of Ampersand Capital Partners.

DealsNorth AmericaUSHealthcareBriefs